Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Editing02:23

RNA Editing

10.2K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
10.2K
Experimental RNAi02:15

Experimental RNAi

8.4K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.4K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

3.3K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.3K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.1K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.1K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.2K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zuranolone: First Approval.

Drugs·2023
Same author

Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

Drugs·2023
Same author

Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Flotufolastat F 18: Diagnostic First Approval.

Molecular diagnosis & therapy·2023
Same author

Omidubicel: First Approval.

Molecular diagnosis & therapy·2023
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Apr 9, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.1K

Apadamtase Alfa: First Approval.

Young-A Heo1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 28, 2024
PubMed
Summary
This summary is machine-generated.

Apadamtase alfa, a recombinant ADAMTS13 enzyme, is now approved in the USA for congenital thrombotic thrombocytopenic purpura (TTP). This marks a significant advancement in enzyme replacement therapy for TTP patients.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Author Spotlight: Enhanced Murine AAA Model Using Elastase to Mimic Human Aneurysms
07:42

Author Spotlight: Enhanced Murine AAA Model Using Elastase to Mimic Human Aneurysms

Published on: July 26, 2024

1.5K

Related Experiment Videos

Last Updated: Apr 9, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.1K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Author Spotlight: Enhanced Murine AAA Model Using Elastase to Mimic Human Aneurysms
07:42

Author Spotlight: Enhanced Murine AAA Model Using Elastase to Mimic Human Aneurysms

Published on: July 26, 2024

1.5K

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
  • ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13) deficiency is the underlying cause of congenital TTP.
  • Current treatment options for congenital TTP are limited, highlighting the need for effective enzyme replacement therapies.

Purpose of the Study:

  • To summarize the development milestones of apadamtase alfa, a recombinant ADAMTS13 enzyme.
  • To highlight the recent US FDA approval of apadamtase alfa for congenital TTP.
  • To provide an overview of the ongoing clinical development for other TTP forms and sickle cell disease.

Main Methods:

  • Review of preclinical and clinical development data for apadamtase alfa.
  • Analysis of regulatory submission and approval processes.
  • Summary of therapeutic applications and ongoing research.

Main Results:

  • Apadamtase alfa (recombinant-krhn; ADZYNMA) is a human recombinant form of ADAMTS13.
  • On November 9, 2023, apadamtase alfa received US FDA approval for prophylactic and on-demand enzyme replacement therapy (ERT) in congenital TTP.
  • The drug is also under regulatory review in the EU and Japan for congenital TTP and in clinical development for immune-mediated TTP and sickle cell disease.

Conclusions:

  • The US approval of apadamtase alfa represents a significant therapeutic advance for patients with congenital TTP.
  • Apadamtase alfa offers a new enzyme replacement therapy option for managing TTP.
  • Further clinical development is ongoing to explore its efficacy in other related hematological conditions.